Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Assessing Decline: Visualising Progression in Huntington’s Disease using a Clinical Dashboard with Enroll-HD Data

Assessing Decline: Visualising Progression in Huntington’s Disease using a Clinical Dashboard... Background: In Huntington’s disease (HD), it remains unclear how symptom severity and rate of symptomatic change relates to age and CAG repeat number (CAGn). It is often difficult for clinicians to assess whether an affected individual’s symptoms are progressing at a similar rate to their affected peers, limiting their ability to intervene at the most appropriate time.Objective: To develop a clinical dashboard that compares an individual’s total motor score (TMS), total functional capacity (TFC) and symbol digit modality test (SDMT) scores against a global cohort, controlling for age and CAGn. The dashboard could then be used by clinicians to identify individuals progressing at a disproportionate rate to his or her peers.Methods: Annualised longitudinal clinical assessment scores from the Enroll-HD dataset were used to generate decline trajectories of the global cohort, allowing cross-sectional (TMS n = 734; TFC n = 734; SDMT n = 694) and longitudinal (TMS n = 270; TFC n = 270; SDMT n = 247) comparison with individual clinical symptom rating scores, to assess decline relative to affected peers.Results: An electronic dashboard with a dynamic output display was created that rapidly compares clinical symptom rating scores of a specific individual against affected peers from a global cohort of comparable CAGn.Conclusions: This study shows the potential for use of multi-centre trial data in allowing comparison of the individual to a larger group to facilitate improved decision-making for individual patients. Visualisation of these metrics via a clinical dashboard demonstrates how it may aid identification of those with disproportionate decline, offering potential for intervention at specific critical points in the disease course. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Huntington's Disease IOS Press

Assessing Decline: Visualising Progression in Huntington’s Disease using a Clinical Dashboard with Enroll-HD Data

Download PDF
9 pages

Loading next page...
 
/lp/ios-press/assessing-decline-visualising-progression-in-huntington-s-disease-2TWqCn0EAI

References (32)

Publisher
IOS Press
Copyright
Copyright © 2017 IOS Press and the authors. All rights reserved
ISSN
1879-6397
eISSN
1879-6400
DOI
10.3233/JHD-170234
pmid
28550266
Publisher site
See Article on Publisher Site

Abstract

Background: In Huntington’s disease (HD), it remains unclear how symptom severity and rate of symptomatic change relates to age and CAG repeat number (CAGn). It is often difficult for clinicians to assess whether an affected individual’s symptoms are progressing at a similar rate to their affected peers, limiting their ability to intervene at the most appropriate time.Objective: To develop a clinical dashboard that compares an individual’s total motor score (TMS), total functional capacity (TFC) and symbol digit modality test (SDMT) scores against a global cohort, controlling for age and CAGn. The dashboard could then be used by clinicians to identify individuals progressing at a disproportionate rate to his or her peers.Methods: Annualised longitudinal clinical assessment scores from the Enroll-HD dataset were used to generate decline trajectories of the global cohort, allowing cross-sectional (TMS n = 734; TFC n = 734; SDMT n = 694) and longitudinal (TMS n = 270; TFC n = 270; SDMT n = 247) comparison with individual clinical symptom rating scores, to assess decline relative to affected peers.Results: An electronic dashboard with a dynamic output display was created that rapidly compares clinical symptom rating scores of a specific individual against affected peers from a global cohort of comparable CAGn.Conclusions: This study shows the potential for use of multi-centre trial data in allowing comparison of the individual to a larger group to facilitate improved decision-making for individual patients. Visualisation of these metrics via a clinical dashboard demonstrates how it may aid identification of those with disproportionate decline, offering potential for intervention at specific critical points in the disease course.

Journal

Journal of Huntington's Disease – IOS Press

Published: Jan 1, 2017

There are no references for this article.